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Abstract
We present a case of disseminated cryptococcal disease, coexisting 
with and mimicking lymphoma. Determination of serum cryptococcal 
antigen should be considered for lymphopenic patients with hemato-
logic malignancies, presenting with unexplained fever, and/or lym-
phadenopathy and/or pulmonary findings. Patients with hematologic 
malignancies treated with chemotherapy regimens are susceptible to 
diverse opportunistic infections. Therefore, in this patient population, 
it is often necessary to obtain a definitive pathologic diagnosis, to 
diagnose uncommon syndromes and guide management.
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Introduction
In patients with hematologic malignancies (HMs), disease 
progression or relapse is frequently the most common consid-
eration in the differential diagnosis of clinical syndromes with 
systemic symptoms and signs. However, patients with HM, es-
pecially those treated with intensive chemotherapy regimens, 
are susceptible to opportunistic bacterial, viral, but also fungal 
infections, including cryptococcal disease [1-3]. Herein, we 
present an unusual case of disseminated cryptococcosis, coex-
isting with and mimicking lymphoma.
Case Report
A 57-year-old man with non-Hodgkin’s lymphoma presented 
to another institution 4 days after his third cycle of rituximab, 
cyclophosphamide, adriamycin, vincristine and prednisone 
(R-CHOP) with headache, malaise and fevers up to 102 °F. 
A chest computerized tomography (CT) showed a right upper 
lobe opacity concerning for pneumonia. He received 11 days of 
empiric vancomycin, cefepime and doxycycline for tickborne 
diseases and was discharged home to complete an additional 
7-day course of levofloxacin and doxycycline. He continued 
to feel unwell and was readmitted to our institution the follow-
ing day with malaise and tachycardia. His past medical history 
was significant for follicular lymphoma, localized below the 
diaphragm with extra-nodal (lumbar spine) involvement diag-
nosed 4 months prior to presentation, hypertension and pulmo-
nary embolism. He worked as a computer programmer and had 
not traveled outside of New England. He had no history of ani-
mal exposures. His vital signs on admission were: temperature 
100.5 °F, blood pressure 130/90 mm Hg, heart rate 130/min, 
respiratory rate 18/min, and oxygen saturation 98% on room 
air; he was not in distress. He had no peripheral lymphadenop-
athy or skin lesions. His cardiovascular, pulmonary, abdomi-
nal and neurologic exams were unremarkable. His laboratory 
workup was notable for lymphopenia (absolute lymphocyte 
count of 250 cells/μL) and hyponatremia (125 mEq/L). Blood, 
urine and sputum cultures were negative. Positron emission 
tomography/CT (PET/CT) performed to evaluate for lympho-
ma progression showed enlarged, fluoro-2-deoxy-D-glucose 
(FDG)-avid mediastinal lymphadenopathy, which was new 
compared to 3 months prior, and had a maximum standardized 
uptake value (SUV) of 7, suggestive of active lymphoma (Fig. 
1A). A bronchoscopy with ultrasound-guided fine-needle aspi-
ration of a mediastinal lymph node was performed.
Hematoxylin-eosin (Fig. 1B) and mucicarmine (Fig. 1C) 
stains of an endobronchial ultrasound-guided fine-needle as-
pirate from the lymph node revealed many encapsulated yeast 
forms with narrow-based budding, morphologically consist-
ent with Cryptococcus species, and no malignant cells. Serum 
cryptococcal antigen titer was 1:128. CD4+ lymphocyte count 
was 78 cells/μL and he was HIV negative. Although the head-
ache that he initially presented with had resolved, a lumbar 
puncture was performed [1]. The opening pressure was 28 mm 
Hg. The cerebrospinal fluid (CSF) white blood cell count was 
365 cells/μL, 87% of which were neutrophils, and protein was 
elevated (416 mg/dL, normal range: 40 - 70 mg/dL). Crypto-
coccal antigen in the CSF was also positive (1:128), and CSF 
cultures grew Cryptococcus neoformans.
Our patient received induction treatment with liposomal 
amphotericin-B (5 mg/kg daily) and 5-flucytosine (100 mg/kg 
Manuscript accepted for publication January 06, 2016
aDivision of Infectious Diseases, Brigham and Women’s Hospital and Dana-
Farber Cancer Institute Harvard Medical School, Boston, MA, USA
bDivision of Infectious Diseases, Warren Alpert Medical School of Brown 
University, Providence, RI, USA
cDepartment of Pathology, Brigham and Women’s Hospital and Dana-Farber 
Cancer Institute Harvard Medical School, Boston, MA, USA
dCorresponding Author: Dimitrios Farmakiotis, 593 Eddy Street, Gerry House 
113, Providence, RI 02903, USA. Email: dimitrios.farmakiotis@lifespan.org; 
Alexis Liakos, Brigham and Women’s Hospital, PBB-A4, 75 Francis St, Bos-
ton, MA 02115, USA. Email: aliakos@partners.org
doi: http://dx.doi.org/10.14740/jocmr2458w
Articles © The authors   |   Journal compilation © J Clin Med Res and Elmer Press Inc™   |   www.jocmr.org258
An Avid Imitator J Clin Med Res. 2016;8(3):257-259
daily) for 2 weeks [1]. His symptoms resolved, repeat CSF 
cultures were negative, and he transitioned to oral fluconazole 
800 mg daily for 8 weeks, and 400 mg daily until completion 
of chemotherapy, with the plan to continue 200 mg of flucona-
zole daily (maintenance) indefinitely, at least until lymphocyte 
count recovery [1].
Discussion
Between 1956 and 1972, the frequency of cryptococcal infec-
tion in patients with chronic lymphocytic leukemia and Hodg-
kin’s lymphoma was estimated to be 24.3 and 13.3 per 1,000 
patients, respectively [2]. However, in a more recent cohort 
[3], the incidence of cryptococcosis at a large cancer center 
was 18/100,000 admissions, between 1989 and 1999. Further-
more, infectious lymphadenitis was observed in 3.9% of lymph 
node biopsies among patients with chronic lymphocytic leuke-
mia and small-cell lymphoma at one center between 2003 and 
2012, but only one case was due to Cryptococcus neoformans 
[4]. The lower rates of documented cryptococcal disease re-
cently may be related to increased use of azole prophylaxis in 
cancer patients who are at risk for invasive fungal infections, 
particularly those with HM.
Cryptococcosis typically affects patients who have im-
paired cell-mediated immunity or receive high-dose steroids 
[3, 5-8]. In two case series of cancer patients with proven cryp-
tococcal infection, 83% [2] and 65% [3] had lymphoprolifera-
tive disorders, most of whom had advanced cancer and were 
heavily treated. We know little about the risk for cryptococ-
cosis in presumably lower net states of immunosuppression, 
for example with low-intensity chemotherapy, or early in the 
course of lymphoma treatment. In the two studies mentioned 
above, 100% [2] and 61% [3] of affected patients had signifi-
cant lymphopenia, an important risk factor for cryptococcal 
disease, as exemplified in the present and previous case reports 
[5-7].
The clinical and radiological presentation of cryptococ-
cosis in cancer patients is non-specific and frequently mimics 
progression of primary malignancy or metastatic disease [3, 
Figure 1. (A) PET/CT showing enlarged, FDG-avid mediastinal lymphadenopathy. (B) Hematoxylin-eosin and (C) mucicarmine 
stains of an endobronchial ultrasound-guided fine-needle aspirate from the mediastinal lymph node showing many encapsulated 
yeast forms with narrow-based budding, morphologically consistent with Cryptococcus species. 
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5, 7, 9]. In one study of cancer patients with cryptococcal dis-
ease, pulmonary cryptococcosis was initially misdiagnosed as 
cancer in 35%, healthcare-associated pneumonia in 22%, and 
indeterminate lung nodules in 19% [3]. 18-FDG PET/CT is 
often used to differentiate between benign and malignant le-
sions, and an SUV of approximately 5 is typically considered 
a reliable cutoff [5]. Nevertheless, in our patient, cryptococcal 
involvement of lymph nodes manifested with an SUV of 7, 
and in another similar case with an SUV of 13 [5]. In a series 
of seven patients with pulmonary cryptococcal lesions, SUV 
values ranged between 2.2 and 11.6 [9]. It should be noted that 
clinical and radiological responses to chemotherapy observed 
in other lymphoma areas usually favor infectious causes of 
new FDG-avid lesions.
Immunocompromised patients may have atypical clini-
cal and radiographic presentations of infectious diseases, so 
pathologic confirmation is often necessary to make a correct 
diagnosis. As this case demonstrates, cytologic sampling can 
readily demonstrate the presence of fungal organisms, with-
out the delays involved with special stains and/or fungal cul-
tures. Accurate diagnosis is particularly important for targeted 
antifungal treatment, given the emerging threat of resistance 
among medically important fungi, as a result of increased em-
piric and prophylactic use of antifungal agents [10].
In conclusion, cryptococcal disease can coexist with and 
mimic lymphoma. Determination of serum cryptococcal anti-
gen should be considered for lymphopenic patients with unex-
plained fever, lymphadenopathy, and pulmonary findings. The 
present report highlights the importance of obtaining a defini-
tive pathologic diagnosis to diagnose uncommon syndromes 
and guide treatment in patients with hematologic malignan-
cies.
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